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ABSTRACT 
 
IDENTIFICATION OF BODY FLUIDS BY MRNA ANALYSIS WITH MINION NANOPORE 
SEQUENCING 
Mary Jessamine Michaels 
Western Carolina University (May 2018) 
Director: Kelly Grisedale, PhD. 
 
The identification of body fluids present on evidence items in a criminal investigation can be 
vital to understanding the nature of a crime, particularly in cases of sexual assault.  Although 
crime labs can confirm the presence of body fluids like semen and blood on a piece of evidence 
using traditional serological techniques, they cannot confirm the presence of saliva or vaginal 
fluid or differentiate peripheral blood from menstrual blood.  Due to the unique patterns of gene 
expression in different cell types, different body fluids contain distinct messenger RNA (mRNA) 
molecules, which can be analyzed to generate mRNA profiles for confirmatory identification of 
body fluids.  High throughput sequencing methods present the opportunity to generate large 
amounts of data from low level forensic samples that is not achievable with more traditional 
techniques.  In this study, the MinION sequencer by Oxford Nanopore Technologies (ONT), 
which is a small and affordable high throughput sequencer that generates data rapidly and in real 
time, was assessed to determine its ability to generate high quality data from forensic type 
samples.  Semen, saliva, blood, vaginal fluid, and menstrual blood from eight different donors 
were collected on sterile swabs.  Additionally, a tenfold dilution series was performed on semen, 
blood, and saliva samples from three donors each and decreasing volumes of semen were 
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pipetted onto vaginal swabs from three sets of donors.  DNA and RNA were co-extracted from 
half swabs.  DNA fractions were taken forward for short tandem repeat (STR) analysis.  For 
RNA fractions, cDNA was generated, and a multiplex PCR targeting two genes per body fluid 
was performed.  Amplicons were sequenced on the MinION with the 1D Ligation Sequencing 
Kit by ONT.  Full DNA profiles were obtained for all semen, blood, and menstrual blood 
samples, and most of the saliva and vaginal fluid samples.  Profiles were obtained for diluted 
semen, saliva, and blood samples, and mixed profiles were obtained for the semen/vaginal fluid 
mixture samples.  The multiplex PCR was highly specific for each body fluid, with little to no 
cross reactivity.  The MinION was able to obtain at least 1,000X coverage of target genes and 
little to no off target reads, even for some diluted samples.  Both vaginal fluid and semen genes 
were detected in mixture samples.  Optimization of the MinION sequencing workflow to 
maximize read counts and minimize costs should be explored.  Despite the high input 
requirements stated by ONT for sequencing, the MinION appears to be able to generate high 
quality data with lower DNA/RNA input.
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CHAPTER ONE: INTRODUCTION 
 
Human body fluids discovered at a crime scene can be used as evidence to identify 
victims or suspects, or to link victims and suspects to each other or to specific crime scenes.  
When crime labs receive items of evidence, they first analyze the evidence to determine what 
body fluids are present, which helps to give context to the evidence items and may assist in 
reconstructing the crime event in question.  Once serological testing is completed, evidence 
items are taken forward for DNA analysis to identify the individual who contributed the body 
fluid.  The combination of serological and DNA analysis results allows investigators to link a 
particular individual to a crime scene and presents information that gives them a better idea of 
the circumstances surrounding the crime.  Although crime labs can confirm the presence of body 
fluids like semen and blood on an item of evidence using traditional serological techniques, these 
tests can be laborious and can consume much of the evidence sample. Furthermore, many crime 
labs are not able to confirm the presence of saliva or vaginal secretions or differentiate peripheral 
blood from menstrual blood.  Identifying these body fluids is important in oral or digital assaults, 
when the presence or absence of semen is not informative within the context of the assault, or 
when menstrual blood must be differentiated from blood present due to trauma.  Tests for these 
body fluids are presumptive only, so there is a need in the field of forensics for robust and 
reliable tests that can confirm the presence of various body fluids that may be present on a 
sample.    
Molecular body fluid identification techniques 
 The identification of body fluids on items of evidence can be vital to understanding the 
nature of a crime.  Current serological techniques are completed separately and require multiple 
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cuttings from the evidence item in question, making them time consuming and inefficient.  In 
addition, many forensic laboratories lack tests that are able to confirm the presence of biological 
fluids like saliva and vaginal secretions. 1  Emerging molecular techniques for body fluid 
identification allow for the ability to confirmatively identify various body fluids, as well as allow 
for the potential to identify different types of body fluid with one all-inclusive test.  Many of 
these techniques are founded in differential gene expression levels in body fluid cells.  Different 
cell types have unique patterns of gene expression within the cell, creating distinct profiles for 
different body fluid types. 2  Specific messenger RNA (mRNA) markers for various body fluids 
have been identified and can be used for confirmatory body fluid testing.  Analysis of 
microRNAs and DNA methylation patterns have also been used for body fluid identification.  
MicroRNAs, which are less subject to degradation, are fairly specific for semen and blood, but 
are less specific for saliva and vaginal secretions, requiring a greater number of markers for 
positive identification. 3  DNA methylation pattern analysis often involves interpreting the level 
of methylation, rather than just the presence or absence of a marker, making interpretation less 
clear. 3  The highly specific and sensitive markers that have been identified for mRNA make 
interpretation of results easier. 
 In the past, the use of mRNA for body fluid identification has been questioned due to its 
unstable nature.  RNA is more susceptible to degradation than DNA and is consequently less 
stable and more difficult to work with. 1  However, over the past decade, many studies have 
shown that RNA is detectable in forensic type samples, and robust and reliable protocols using 
various analysis methods, including sequencing, have been developed.  Although hot or humid 
conditions can often be detrimental to the RNA in the sample, mRNA profiles are obtainable 
from saliva stains for at least 365 days and in vaginal secretions for at least 547 days when 
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samples were stored at room temperature. 4  Zhao et al. (2016) found that the hemoglobin 
markers HBA and HBB were detectable in 30 and 50 year old blood stains. 5  Even when 
exposed to harshly dry and humid environments, semen and saliva are detectable for up to 71 
weeks. 6  Saliva and vaginal secretion stains show less sustainability due to greater susceptibility 
to hydrolytic damage over time. 4, 6  Despite this, the RNA found in biological stains appears to 
be stable enough to obtain profiles for identification when samples are properly stored.   
DNA/RNA co-extraction 
 Performing serological testing as part of the DNA analysis workflow means that two 
cuttings must be consumed for each item of evidence.  One cutting is made for body fluid 
identification and another is made for DNA profiling, consuming much of what may be a very 
small sample.  Using RNA analysis for body fluid identification offers the possibility of co-
extraction of DNA and RNA from the same cutting, making analysis more efficient and less 
wasteful.  Although the quantity and integrity of the RNA and DNA extracted using both organic 
co-extraction methods and commercial co-extraction kits have been assessed, no method has 
consistently been shown to be optimized for both DNA and RNA analysis.  Many studies have 
used the AllPrep DNA/RNA Mini Kit (Qiagen) for co-extraction. 7- 9  Although this co-extraction 
kit appears to be sufficient for recovery of DNA, the recovery of RNA is poor in comparison to 
other methods. 7- 9  Grabmuller et al. (2015) found that RNA extraction was most efficient with 
the NucleoSpinÒ miRNA Kit (Macherey-Nagel) and the RNeasyÒ Mini Kit (Qiagen).  However, 
the NucleoSpinÒ protocol involves more handling of the samples, increasing the potential for 
cross contamination. 7  Conversely, the RNeasyÒ kit can be automated, which would allow for 
additional contamination prevention.  In their study, which compared the performance of 
different RNA/DNA co-extraction methods, Grabmuller et al. (2015) isolated DNA from the 
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lysate waste after the initial spin in the RNeasyÒ kit workflow and extracted DNA from it with 
the PrepfilerÒ Forensic DNA Extraction Kit (Life Technologies).  Although the AllPrep kit had 
slightly better recovery, a comparable amount of DNA was recovered with the RNeasyÒ kit. 7  
Reliability of mRNA markers 
 Gene markers used in multiplex RNA analyses must be both body fluid specific and 
sensitive enough to detect in the low template samples generally encountered in forensic 
casework.  Additionally, primers for such markers must eliminate the possibility of amplification 
of genomic DNA, which is done by using primers that either span exon-exon boundaries or span 
an exon and intron region that would allow DNA amplicons to be eliminated due to size 
differences. 10  While semen, blood, and menstrual blood markers appear to be more sensitive 
and specific, some saliva and vaginal secretion markers exhibit non-specific amplification. 11- 15  
For semen samples, the Seminogelin 1 (SEMG1) and Protamine 1 (PRM1) genes appear to be 
highly successful. 11- 15  The seminogelin gene encodes the main protein present in seminal fluid 
that entraps spermatozoa cells and is essential for flagellar movement of spermatozoa. 16  
Protamine 1 encodes for a protein that forms a complex with protamine 2 and histones in 
spermatozoa cells enabling packaging of chromatin for epigenetic control of expression. 17  
Additionally, SEMG1 has been successful for identifying semen from vasectomized donors, 
while PRM1 has been successful for identification of semen from fertile donors. 11   
Differentiation between peripheral and menstrual blood can be achieved by targeting 
matrix metalloproteinase genes (MMP7, MMP10, and MMP11), which are involved in the 
cleavage of cell surface receptors and breakdown of the extracellular matrix, leading to the 
dissociation of uterine tissues during menstruation. 18  These have been shown to be highly 
specific to menstrual blood samples. 10, 19  Among other peripheral blood specific genes, the d-
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Aminolevulinate synthase (ALAS2) and Hemoglobin alpha locus 1 (HBA) genes have been 
shown to be highly sensitive and specific. 5, 10, 20  ALAS2 is a gene that encodes for an enzyme 
that catalyzes the synthesis of heme in erythrocytes, and HBA is a subunit of hemoglobin, both 
of which work together to allow for the transport of oxygen through the bloodstream. 21, 22  Due 
to the presence of peripheral blood in menstrual blood, both peripheral blood and menstrual 
blood markers are detectable in these samples.  Because hemoglobin genes are highly expressed 
in blood cells, the HBA gene has been shown to be detectable in aged stains. 10 
 Due to the expression of similar genes, like mucins, in both saliva and vaginal secretion 
samples, cross reactivity has been observed in many studies.  Targeting of the human beta-
defensin 1 (HBD1) and mucin 4 (MUC4) genes in vaginal secretions have shown cross reactivity 
with saliva samples. 10, 19  The mucin 7 (MUC7) gene targeted for saliva samples has been shown 
to be cross reactive with vaginal fluid samples. 12  Despite this, the Histatin 3 (HTN3) and 
Statherin (STATH) genes appear to be both sensitive and specific markers for saliva samples. 12, 
15  Histatin 3 encodes a salivary protein that has antimicrobial properties and interacts with heat 
shock proteins and cyclin dependent kinase (CDK) inhibitors to promote progression through the 
cell cycle. 23  Statherin encodes a protein that binds to hydroxyapatite found on tooth enamel to 
prevent calcium phosphate buildup. 24  Although STATH appears to be a good marker for saliva, 
it is expressed less than HTN3 and is therefore slightly less sensitive. 15   
The myozenin 1 (MYOZ1) and cytochrome p450, family 2, subfamily B, polypeptide 7, 
pseudogene 1 (CYP2B7P1) genes have been shown to be more specific for vaginal secretions 
than HBD1 and MUC4. 10  MYOZ1 encodes an a-actin and g filament binding protein that 
functions in sarcomeres and is primarily expressed in skeletal muscle. 25  CYP2B7P1 is a non-
coding RNA expressed highly in vaginal fluids and internal organs such as the liver and lungs. 26  
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Because the only other samples in which these mRNAs would be highly expressed is in deep 
tissues or organs, theses markers should be specific for vaginal fluid samples found in a forensic 
context.  Although targeting of Lactobacillus genes in vaginal fluid samples has been successful, 
there is a greater risk of contamination and non-specific amplification of similar or related 
microbial species present on other parts of the body. 10  In addition to targeting body fluid 
specific markers, housekeeping genes should also be targeted for use as a positive control.  
Glucose 6-phosphate dehydrogenase (G6PDH) is a protein that produces reduced nicotinamide 
adenine dinucleotide phosphate (NADPH), which is an important electron donor involved in 
cellular respiration, and 18S rRNA is a part of the ribosomal subunit in eukaryotes. 27  Because 
both of these are expressed in all tissues, they have been shown to be successful housekeeping 
targets. 10, 11 
MinION nanopore sequencing 
 In the past, capillary electrophoresis has primarily been used to analyze target mRNAs.  
However, due to the high throughput of next-generation sequencing technologies, more studies 
are using these platforms for mRNA analysis.  One fairly new high throughput sequencer is the 
Oxford Nanopore Technologies (ONT) MinION.  The MinION is small, portable, relatively 
inexpensive in comparison to other next-generation DNA sequencers, and produces data in real-
time. 28  Rather than employing the sequencing by synthesis method utilized in other platforms, 
the MinION uses protein nanopores embedded in a membrane through which an electrical 
current is applied.  An enzyme separates DNA strands and pushes a single strand through the 
nanopore one base at a time.  As the strand is passed through, the MinION detects disruptions in 
the membrane’s electrical current. 29  Because different combinations of nucleotides cause 
distinctive disruptions in the current, the software can call bases according to those current 
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changes.  Although this new technology is promising, there are some issues.  Accuracy of 
basecalling, particularly for longer reads, has been shown to be less than with other sequencing 
methods. 28, 29  However, changes in the sequencing chemistry have increased accuracy and 
precision to up to 99% for genotyping. 29  In addition, most of the sequencing kits for the 
MinION have a high DNA input requirement, which is not ideal for forensic samples.  However, 
its ability to sufficiently sequence forensic type samples is not fully known.  
 Oxford Nanopore Technologies offers two methods of sequencing (Ligation sequencing 
and Rapid sequencing) on the MinION.  The Rapid Sequencing Kits are designed only for high 
molecular weight gDNA, and are therefore not suitable for mRNA or amplicon analysis.  The 
Ligation Sequencing Kits, which are able to sequence gDNA, cDNA, and amplicons offer two 
methods of sequencing: 1D and 1D2.  The 1D Ligation Sequencing Kit sequences only one 
strand of the DNA, while the 1D2 Ligation Sequencing Kit allows for sequencing of both the 
template and complimentary strands, allowing for better accuracy.  However, the 1D2 Ligation 
Kit has a longer library preparation time and was more expensive than the 1D Ligation Kit at the 
start of this study, although the kits are now the same price.  The ligation kits library preparation 
starts by dA-tailing DNA fragments and ligating adapters to ends. 30  The adapters are attached to 
an enzyme that ratchets the DNA strand through the nanopore one base at a time. 30  A 
specialized sequence in the adapter prevents activation of the enzyme until contact with a 
nanopore on the flow cell is achieved. 30  During an adapter clean-up elution step, tethers are 
added to adapter-ligated ends, which allows fragments to locate to nanopores upon loading the 
library onto the flow cell. 30  Figure 1 shows the library preparation steps for 1D Ligation 
Sequencing Kit. 
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Figure 1.  Library preparation for ONT’s 1D Ligation Sequencing Kit, consisting of end-
prepping of DNA fragments, ligation of adapters to fragment ends, and attachment of tethers to 
fragment ends. 30   
 
 
Purpose of the study 
 The purpose of this study is to explore a rapid method for identifying body fluids from 
forensic samples.  Because the MinION DNA sequencer is very small, inexpensive, and has a 
rapid data turnaround in comparison to other high throughput DNA sequencers, it could be ideal 
for the processing of evidence in crime laboratories.  To examine the reliability of this method, 
semen, saliva, peripheral blood, vaginal fluid, and menstrual blood from 8 different donors per 
body fluid were analyzed using the MinION sequencer.  Dilution series of semen, blood, and 
saliva, as well as mixtures of semen and vaginal fluid, were also analyzed.  A multiplex PCR 
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targeting two specific genes per body fluid was optimized, including two housekeeping gene 
targets as endogenous controls.  Because the MinION sequencer is a new technology, not much 
is known about how well it obtains high quality data from forensic samples.   This study 
explored the ability of this new sequencer to work in a forensic setting and determined the 
robustness, reliability, and reproducibility of the results of analysis of various body fluid 
samples. 
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CHAPTER TWO: MATERIALS AND METHODS 
 
Sample Collection 
 Body fluid samples were collected from 8 different donors per body fluid type.  Semen 
and menstrual blood samples from 8 donors were ordered from Lee BioSolutions™.  Saliva, 
peripheral blood, vaginal fluid, and menstrual blood samples were collected from 8 different 
donors per body fluid with fully informed consent.  Menstrual blood and vaginal fluid samples 
were collected on sterile swabs by inserting the swab approximately 5 cm (2 inches) into the 
vaginal canal and rotating approximately 5 times.  All donors of vaginal fluid or menstrual blood 
swabs had not engaged in vaginal sex in the seven days prior to collection.  Liquid semen, saliva, 
peripheral blood, and menstrual blood were pipetted onto sterile swabs in 30 µl aliquots and 
allowed to dry overnight.  Tenfold dilution series for semen, saliva, and blood from 3 donors 
each were prepared and 30 µl of each diluted sample (1:10, 1:100, and 1:1,000) was pipetted 
onto sterile swabs.  Vaginal fluid and semen mixture samples from 3 sets of donors were set up 
by pipetting 7.5 µl, 15 µl, and 30 µl of neat semen onto vaginal swabs.  Half swabs were used for 
DNA/RNA co-extraction.  Additionally, buccal swabs from each donor were collected to serve 
as DNA reference samples.   
DNA/RNA co-extraction 
 A DNA/RNA co-extraction method adapted from Grabmuller et al. (2015) was used. 7  
The RNeasyÒ Mini Kit and the Prepfilerâ Forensic DNA Extraction Kit were used for co-
extraction of DNA and total RNA.  350 µl of Buffer RLT from the RNeasyÒ kit and 3 µl of 
Dithiothreitol (DTT) were added to half swabs and incubated at 56ºC for 1 hour.  20 µl of the 
lysate was removed after incubation and used for extraction of DNA with the Prepfilerâ Forensic 
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DNA Extraction Kit. 31  300 µl of Prepfilerâ Lysis Buffer was added to the DNA fraction without 
incubation.  Then, DNA was extracted from the sample according to the manufacturer’s protocol. 
31  The remaining lysate was used for RNA extraction with the RNeasyÒ Mini Kit according to 
the manufacturer’s protocol. 32 
DNA/RNA quantification 
DNA samples were quantified using the Quantifiler® Trio DNA Quantification Kit 
according to the manufacturer’s protocol. 33  The concentration of total RNA was analyzed with 
the Agilent RNA 6000 Pico Kit according to the manufacturer’s protocol. 34  An RNA integrity 
number (RIN) was obtained to assess any sample degradation.  An RIN of 10 signifies that the 
RNA sample is completely intact, while an RIN of 1 signifies that the sample is totally degraded. 
35 
DNase treatment and reverse transcription 
To eliminate any DNA contamination, total RNA samples were DNase treated using the 
TURBO DNA-freeTM Kit according to the manufacturer’s protocol.  1 µl of TURBOTM DNase 
was added to purified RNA samples with a 0.1 volume of 10X TURBO DNase buffer for routine 
DNase treatment.  After incubation at 37°C for 25 minutes, 2 µl of DNase Inactivation Reagent 
was added, and samples were incubated at room temperature for 5 minutes before centrifugation. 
36  DNase treated samples were then reverse transcribed using the ProtoScriptÒ First Strand 
cDNA Synthesis Kit according to the manufacturer’s protocol. 37   
STR profiling 
 The GlobalFilerTM PCR Amplification Kit was used for STR analysis of DNA fractions 
according to the manufacturer’s protocol. 38  Amplified samples were then analyzed using the 
3500xL Genetic Analyzer, and the data obtained from STR analysis was analyzed using 
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GeneMapperTM ID-X Software.  Profiles obtained from body fluid samples were compared to 
reference profiles to assess profile completeness.  The number of alleles observed for the 21 
autosomal markers was determined for each sample, and percent completeness of the profile was 
calculated. 
Multiplex PCR 
Short targets 
A multiplex PCR was designed to target two genes for each body fluid type. Primer 
sequences for this multiplex were taken from the literature. Two markers for semen (SEMG1 and 
PRM1 11), saliva (HTN3 and STATH 39), peripheral blood (HBA 40 and ALAS2 41), vaginal 
fluid (CYP2B7P1 42 and MYOZ1 41), and menstrual blood (MMP7 and MMP11 11) were 
included in the multiplex.  Additional sequences required for downstream multiplexing with the 
PCR Barcoding Kit I by Oxford Nanopore Technologies were added to the 5’ ends of primer 
pairs. 43  Primer sequences for all markers are shown in Table 1.  Each primer pair was tested 
with each body fluid type in singleplex reactions to ensure amplification of the proper gene 
target and to ensure no non-specific amplification of off-target body fluids was observed.  For 
singleplex PCR, 5 units of AmpliTaq GoldTM DNA polymerase (1.0 µl in a 25 µl reaction), 2.5 
µl of 10X PCR Buffer, 1.5 µl of 25 mM MgCl2, 2.5 µl of 1.6 µg/µl BSA, 0.5 µl of 10 mM dNTP 
mix, 1.5 µl of each primer (0.8 µM final concentration), 11.5 µl of RNase-free water, and 2.5 µl 
of cDNA were combined.  The following cycling parameters were used for PCR: initial 
denaturation at 95°C for 11 minutes and 36 cycles of 95°C for 10 seconds, 63°C for 30 seconds, 
and 72°C for 30 seconds. 
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Table 1.  Gene target information and primer sequences for multiplex PCR of short amplicons. 
 
 
A 10X primer mix with 12 primer pairs was prepared containing 2.0 µM of each primer.  
For the multiplex PCR, 12.5 µl of 2X QIAGEN Multiplex PCR Master Mix, 7.5 µl of RNase-
free water, 2.5 µl of 10X primer mix, and 2.5 µl of cDNA was combined for a total reaction 
volume of 25 µl.  Because of unsatisfactory yield of amplification of vaginal fluid and menstrual 
blood markers, a gradient multiplex PCR was done with vaginal fluid and menstrual blood 
samples to find the optimal annealing temperature, which was found to be 60°C.  The following 
cycling conditions were used for PCR: initial denaturation at 95°C for 15 minutes, 40 cycles of 
95°C for 30 seconds, 60°C for 90 seconds, and 72°C for 90 seconds, and a final extension at 
72°C for 10 minutes. 44  In addition, one sample of each body fluid, one of each of the 1:10 
dilutions of semen, saliva, and blood, and one of the semen/vaginal fluid mixture samples was 
sequenced via Sanger sequencing to verify amplicon length observations. 
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Long targets 
Because the length of amplicons needed to obtain high quality sequences with the 
MinION is generally above 300 base pairs (bp), another multiplex PCR was designed to target 
longer fragments (³ 300 bp).  All of the same gene targets except for PRM1, MMP11, and the 
two housekeeping genes, 18S rRNA and G6PDH, were targeted in this multiplex.  Because 
PRM1 is too short to achieve the 300 bp amplicon length, protamine 2 (PRM2) was used to 
target semen instead of PRM1.  Due to the unsuccessful amplification of the markers for 
menstrual blood in the first multiplex, MMP11 was replaced by another matrix 
metalloproteinase, MMP10, which has been shown to be more highly expressed in menstrual 
blood cells than MMP11. 19  Because of the high sensitivity of 18S rRNA marker, and the 
unsuccessful amplification of G6PDH in many samples, the two housekeeping genes were 
replaced by ubiquitin C (UBC) and beta-2-microglobin (B2M), which have been successfully 
used in a series of collaborative efforts by the European DNA profiling group (EDNAP). 12, 19, 45  
Primer sequences were designed using the Integrated DNA Technologies® (IDT®) PrimerQuest 
Tool. 46  Due to the increased susceptibility of mRNA to degradation, the ends of mRNA strands 
were avoided as targets, so most primers were designed to amplify the innermost area of the 
mRNA strand.  Primers were also designed to span exon-exon junctions to avoid amplification of 
contaminating DNA.  The universal ONT barcoding sequences were added to the 5’ ends of 
primers.  Primer sequences used in this multiplex PCR are shown in Table 2.  
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Table 2.  Gene target information and primer sequences for multiplex PCR of long amplicons. 
 
 
All primers were tested in singleplex reactions to ensure proper gene target amplification 
and to ensure there is no non-specific amplification of off-target body fluids.  For the singleplex 
PCR, 5 units of AmpliTaq GoldTM DNA polymerase (1.0 µl in a 25 µl reaction), 2.5 µl of 10X 
PCR Buffer, 1.5 µl of 25 mM MgCl2, 2.5 µl of 1.6 µg/µl BSA, 0.5 µl of 10 mM dNTP mix, 1.5 
µl of each primer (0.8 µM final concentration), 11.5 µl of RNase-free water, and 2.5 µl of cDNA 
were combined.  For the multiplex, 10X primer mix with all 12 primer pairs was prepared 
containing 2.0 µM of each primer.  The multiplex PCR was prepared with 12.5 µl of 2X 
QIAGEN Multiplex PCR Master Mix, 7.5 µl of RNase-free water, 2.5 µl of 10X primer mix, and 
2.5 µl of cDNA was combined for a total reaction volume of 25 µl.  A gradient multiplex PCR 
was performed to find the best annealing temperature for primers in the multiplex, which was 
found to be 62°C.  The following cycling conditions were used for PCR: initial denaturation at 
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95°C for 15 minutes, 40 cycles of 95°C for 30 seconds, 62°C for 90 seconds, and 72°C for 90 
seconds, and a final extension at 72°C for 10 minutes. 44  
Quantification and cleanup of PCR products 
 All samples were analyzed on the Agilent 2100 Bioanalyzer using the DNA 1000 kit 
according to the manufacturer’s protocol. 47  After quantification, samples were cleaned with 
ExoSAP-ITTM according to the manufacturer’s protocol. 48  Total concentrations of amplicons 
present in each sample after ExoSAP-ITTM were calculated from the Bioanalyzer data to move 
forward with barcoding PCR. 
Library preparation 
Barcoding PCR 
 The PCR Barcoding Kit I by ONT, which contains 12 different barcodes for 
multiplexing, was used.  A barcoding PCR was optimized using the TaKaRa Taq PCR kit.  The 
barcoding PCR was set up by combining 0.5 µl of TaKaRa Taq Polymerase, 5 µl of 10X PCR 
Buffer (with Mg2+), 8 µl of a 2.5 mM each dNTP mixture, 0.5 ng of PCR product, 1 µl of 
barcode primers, and 30.5 µl of water. 49  The following cycling parameters were used: initial 
denaturation at 95°C for 3 minutes, 15 cycles of 95°C for 15 seconds, 62°C for 15 seconds, 72°C 
for 30 seconds, and a final extension at 72°C for 5 minutes.  After PCR, amplification products 
were visualized and quantified on the Agilent 2100 Bioanalyzer using the DNA 1000 kit. 47  
Samples were then cleaned with Agencourtâ AMPureâ XP beads according to the 
manufacturer’s protocol. 50  A 1.8 volume of AMPureâ beads was added to PCR products for 
cleanup.   
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End Preparation 
 End preparation of the barcoded library was performed according to the 1D PCR 
barcoding amplicons (SQK-LSK108) protocol described by ONT. 43  The library input for end 
prep with ONT’s Ligation Sequencing Kit 1D is 1 µg of DNA in 45 µl.  Because the total 
concentration of the samples in this study were not high enough to achieve the 1 µg input 
requirement, equal volumes of all samples for a sequencing run were added to the end prep 
reaction with a final volume of 45 µl.  5 µl of the DNA CS (control strand) from the sequencing 
kit, 7 µl of Ultra II End-prep reaction buffer, and 3 µl of Ultra II End-prep enzyme mix (New 
England Biosystems) were added to 45 µl of the pooled, barcoded library.  The end-prep reaction 
mix was incubated at 20°C for 5 minutes and 65°C for 5 minutes.   
The end-prepped libraries were then cleaned by adding 60 µl of Agencourtâ AMPureâ 
beads and incubating on a rotator mixer for 5 minutes at room temperature. Samples were then 
pelleted on a magnet and the supernatant was removed.  Two washes with 200 µl of freshly 
prepared 70% ethanol were performed, removing the supernatant after 30 seconds.  All ethanol 
was removed from the sample while on the magnet, and the beads were allowed to dry for 3 
minutes.  31 µl of nuclease-free water was then added as an elution buffer, and the samples were 
allowed to incubate for 2 minutes at room temperature.  The beads were then pelleted on the 
magnet, and the purified library was retained.  The success of the end-prep reaction was assessed 
on the Agilent 2100 Bioanalyzer with the DNA 1000 kit. 
Adapter ligation 
 Adapter ligation was performed according to the 1D PCR barcoding amplicons (SQK-
LSK108) protocol. 43  The suggested input of end-prepped DNA for adapter ligation is 0.2 
pmoles for a 10:1 adapter to fragment ratio.  For the samples in this study, all 30 µl of end-
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prepped DNA was added to the adaptor ligation reaction, regardless of concentration.  20 µl of 
adaptor mix (ONT) and 50 µl of Blunt/TA Ligation Master Mix (NEB) were added to 30 µl of 
end-prepped DNA and incubated at room temperature for 10 minutes.  Excess adapter was 
removed by adding 180 µl of AMPureâ XP beads and mixing.  Samples were then incubated on 
a rotator mixer for 5 minutes at room temperature and placed on a magnetic rack to remove the 
supernatant.  Two washes with 140 µl of the Adapter Bead Binding Buffer (ONT) were 
performed, and the supernatant was removed after 30 second incubations.  The pellet was re-
suspended in 15 µl of the Elution Buffer (ONT) and incubated for 10 minutes at room 
temperature.  The beads were pelleted and the eluate was retained.   
Priming and loading the flow cell 
 MinION flow cells (R9.4) were primed with a priming mix containing 576 µl of Running 
Buffer with Fuel Mix (RBF) and 624 µl of nuclease free water.  800 µl of the priming mix was 
added to flow cells via the priming port with the sample port closed and allowed to incubate for 5 
minutes.  Then 200 µl of the priming mix was added to flow cells with the sample port open.  
Libraries were prepared by adding 35 µl of the RBF, 2.5 µl of nuclease free water, and 25.5 µl of 
Library Loading Beads (LLB) to 12 µl of DNA.  75 µl of library was added to flow cells in a 
drop wise fashion through the sample port.  The SQK-LSK108 protocol in the MinKNOW 
software was run along with the barcoding workflow in the EPI2ME software monitor the 
success of the run.   
Data Analysis 
 Basecalling was performed on raw data files and reads were bioinformatically parsed into 
sample dependent files based on identification of unique barcodes. Resulting files were saved as 
FAST5 files with the Albacore basecalling software (ONT).  FAST5 files were then converted to 
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FASTA files via Poretools. 51  Sequences were trimmed with Porechop, a program designed to 
identify ONT barcodes and adapters both at the ends of sequences and in the middle of 
sequences.  Adapters identified at the ends of sequences are removed.  When an adapter is found 
in the middle of the sequence, the read is considered a chimera and is split into two separate 
sequences.  Trimming parameters were adjusted to better fit short reads.  Adapter sequences 
were forced to have at least 98% identity to at least 10,000 sequences in the file in order to be 
counted as present (--adapter_threshold 98).  The program checked for adapters in the 150 bases 
at the ends of each sequence (default setting) and removed sequences that had 85% similarity to 
it (--end_threshold 85), without trimming any extra bases (--extra_end_trim 0).  Adapters in the 
middle of the sequence had to have 98% similarity to the adapter sequences to be split (--
middle_threshold 98).  Any sequences after the split that were less than 100 bp in length were 
removed (--min_split_read_size 100).  No additional bases were removed on either side of the 
adapters (--extra_middle_trim_good_side 0 and --extra_middle_trim_bad_side 0).  All other 
parameters were kept at the default settings.  
FASTA files were then uploaded into the CLC Genomics Workbench Software.  All 
sequences less than 150 bp were filtered out with the trimming tool to prevent analysis of primer 
dimers.  Remaining sequences were then mapped to the genes included in the multiplex.  All 
reference gene sequences were obtained from GenBank.  
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CHAPTER THREE: RESULTS 
 
DNA/RNA co-extraction 
 The DNA/RNA co-extraction method appeared to be sufficient to obtain full DNA 
profiles for most of the undiluted body fluid samples, as well as the mixture samples and some of 
the diluted body fluid samples.  Full STR profiles were obtained for all semen and menstrual 
blood samples from Lee Biosolutions™ (Table 3).    Full STR profiles were obtained for six of 
the eight saliva samples, with the remaining two having 50% and 78.6% of complete profiles.  
Full profiles were obtained for seven of the eight blood samples and seven of the eight vaginal 
fluid samples, with the remaining two samples having greater than 90% of a complete profile.    
 
Table 3.  Average DNA quantities and percentage profile completeness based on autosomal STR 
loci for semen, saliva, blood, vaginal fluid, and menstrual blood samples. 
 
 
 
 
 Complete or nearly complete profiles (greater than 90% of a profile) were obtained for 
77.8% of the 1:10 dilutions of body fluids (Table 4).  For semen, full profiles were obtained for 
all three of the 1:10 dilution replicates.  Complete profiles were obtained for only two of the 
three 1:10 saliva dilution replicates.  No complete profiles were obtained for the 1:10 blood 
dilutions, which had an average of 88.9% (± 5.0%) of a complete profile.  No full profiles were 
obtained for 1:100 dilutions.  For semen, one of the 1:100 dilutions had 92.9% of a complete 
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profile, with the remaining two having less than 30% of a complete profile.  For saliva samples, 
one of the dilutions had no alleles present, while the other two had 33% and 17 % of a complete 
profile.  For blood, one of the 1:100 dilution samples had 95.2% of a complete profile.  The other 
samples had less than 20% of a complete profile.  For 1:1,000 semen dilutions, one sample had 
no alleles present, while the other two had less than 20% of a profile.  No profiles were obtained 
for any of the 1:1,000 dilutions of saliva.  For the 1:1,000 dilutions of blood, two samples had no 
alleles present, while the other had less than 5% of a complete profile.   
 
Table 4.  Average DNA sample quantities and percentage profile completeness based on 
autosomal STR loci for 1:10, 1:100, and 1:1,000 dilutions of semen, saliva, and blood. 
 
 
 For the mixture samples, full profiles were obtained for the major contributors (vaginal 
swab donors) for all samples (Table 5).  An average of 57.9% (± 11.3%) of a complete profile 
was obtained for the minor contributors (semen donors) from vaginal swabs with 7.5 µl of 
semen.  An average of 96.03% (± 5.0%) of a complete profile was obtained for minor 
contributors from swabs with 15 µl of semen.  Complete profiles were obtained for minor 
contributors from two of the three swabs with 30 µl of semen, with the remaining replicate 
having 95.2% of a complete profile.   
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Table 5.  Average DNA quantities and percentage profile completeness based on autosomal STR 
loci for vaginal swabs with 7.5 µl, 15 µl, and 30 µl of semen. 
 
 
After extraction, analysis of RNA samples on the Bioanalyzer with the RNA 6000 Pico 
Kit revealed all RNA samples to be highly degraded. The average RIN number for 8 semen, 
saliva, and blood samples and ten menstrual blood samples was 1.93.  12 of the 34 samples 
analyzed with the RNA 6000 Pico Kit could not be assigned an RIN number.  Despite the 
apparent degradation, all samples were taken forward for sequencing.  Because amplification 
was seen in RNA samples after PCR, it appears that the RNA quantification method is not 
informative of the quality and quantity of the RNA in this workflow.  For the rest of the samples 
in this study, the RNA quantitation step was removed, and samples were reverse transcribed 
directly after extraction and DNase treatment.   
mRNA analysis 
Marker specificity for short targets 
 The performance of primers for all mRNA markers was assessed in singleplex to ensure 
no cross-reactivity of body fluids.  The success of PCR was determined on the Agilent 2100 
Bioanalyzer.  The lengths of amplicons produced for each sample were compared to expected 
amplicon lengths.  In singleplex reactions targeting short amplicons, no cross reactivity of body 
fluid specific markers was observed in any of the samples according to the amplicon length data.  
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Amplicons of the proper length were observed for all markers in their respective target body 
fluid, except for MMP7 and MMP11.  Amplicons of the proper length for G6PDH were obtained 
in the multiplex reaction, but not the singleplex reaction.  The MMP7 and MMP11 markers were 
not amplified in the menstrual blood samples obtained from Lee Biosolutions™.  However, an 
amplicon matching the expected length of MMP7 was present in PCR products obtained from a 
vaginal swab that may have had menstrual blood present.  The 18S rRNA marker has shown 
amplification in the multiplex PCR products for reagent blanks and non-template controls, but 
not in any of the singleplex reactions.  However, the signal is low in the reagent blanks in 
comparison to the signal in body fluid samples.  Typical Bioanalyzer results after the multiplex 
PCR for semen, saliva, blood, and vaginal fluid samples are shown in Figure 2.  
 
 
Figure 2.  Bioanalyzer results for (a) a semen sample showing amplicons present at the 
approximate expected lengths for PRM1 (142 bp), SEMG1 (171 bp), 18S rRNA (158 bp), and 
G6PDH (238 bp), (b) a saliva sample showing amplicons present at the approximate expected 
lengths for STATH (133 bp), HTN3 (181 bp), and 18S rRNA (155 bp), (c) a blood sample 
showing amplicons present at the approximate expected lengths for ALAS2 (142 bp), a potential 
combined peak for HBA and18S rRNA (162 bp), and G6PDH (240 bp), and (d) a vaginal fluid 
sample showing amplicons present at the approximate expected lengths for MYOZ1 (136 bp), 
CYP2B7P1 (191 bp),18S rRNA (154bp), and G6PDH (225 bp).  
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For semen samples, amplicons matching the approximate length for PRM1 and SEMG1 
were present in five of the eight samples, and amplicons matching the approximate length for 
PRM1 were present in the other three samples (Table 6).  Amplicons matching the lengths of 
both HTN3 and STATH were seen in seven of the saliva samples, and an amplicon matching 
only HTN3 was seen in one sample.  Amplicons matching ALAS2 were seen in all of the blood 
samples.  Due to the closeness in length of the HBA and18S rRNA markers, the presence of the 
HBA marker cannot be inferred from fragment lengths in the multiplex.  Fragments close to the 
length of the vaginal fluid markers were seen in most of the vaginal fluid samples.  There was no 
amplification of the menstrual blood markers seen in any of menstrual blood samples.   
 
Table 6. Presence of gene markers according to length data in eight semen, blood, saliva, and 
vaginal fluid samples and in ten menstrual blood samples (eight liquid samples and two vaginal 
swabs). 
 
 
 According to BLAST results, Sanger sequencing performed on one sample per body fluid 
type, as well as one of each of the dilution series samples and mixture samples, showed the 
presence of both semen markers in the semen sample.  HTN3 was present in the saliva sample, 
but no sequence was obtained for STATH.  HBA was present in the blood sample, but no 
sequence was obtained for ALAS2.  Sequences matching both CYP2B7P1 and MYOZ1 were 
obtained from the vaginal fluid sample.  No sequence data was obtained for either of the 
menstrual blood gene markers.   
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Sensitivity of short targets 
 For the semen dilution series, amplicons matching the length of PRM1 were observed in 
all three of the 1:10 and 1:100 dilution samples, and was observed in one of the 1:1,000 dilution 
samples (Table 7).  Amplicons near the expected length of SEMG1 were observed in one of the 
three 1:10 and 1:1,000 dilution samples and in all three of the 1:100 dilutions.  For the saliva 
dilution series, amplicons matching the length of HTN3 were seen in all three of the 1:10 
dilution samples, but in none of the 1:100 or 1:1,000 dilutions.  An amplicon near the expected 
length of STATH was seen in only one of the 1:10 dilution samples, with no amplification of 
STATH apparent in the 1:100 or 1:1,000 samples.  For the blood dilution series, an amplicon 
matching the length of HBA was seen in only one of the 1:10 dilution samples.  There was no 
amplification of HBA in the 1:100 or 1:1,000 dilutions.  Additionally, there was no apparent 
amplification of ALAS2 in any of the samples.  For the semen/vaginal fluid mixture series, 
amplicons close to the expected lengths of PRM1 and SEMG1 were seen in all samples.  
Amplicons close to the expected length of CYP2B7P1 were seen in all samples, but MYOZ1 did 
not appear to amplify in any of the samples.   
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Table 7.  Presence of gene markers according to length data in (a) a tenfold dilution series of 
semen, saliva, and blood, and in (b) a mixture series with vaginal swabs combined with 
decreasing volumes of semen (30 µl, 15 µl, and 7.5 µl). 
 
 
 According to the BLAST results, Sanger sequencing performed on one of the 1:10 semen 
dilution samples showed the presence of both semen markers.  For the 1:10 saliva dilution 
sample, a sequence matching HTN3 was observed, but no sequence was obtained for STATH.  A 
sequence matching HBA was seen in the 1:10 blood dilution sample analyzed, but no sequence 
was obtained for ALAS2.  For the mixture sample (vaginal swab with 30 µl of semen), 
sequences for both of the semen markers and for both of the vaginal fluid markers were obtained.   
Marker specificity for long targets 
 Primers targeting longer fragments were tested in singleplex reactions to ensure no 
occurrence of cross reactivity.  There was no non-specific amplification seen in off-target body 
fluids.  However, within target body fluids, there was amplification of fragments approximately 
twice as long as expected fragments.  This appeared to occur more often in the semen samples 
a 
b 
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than other samples.  This non-specific amplification within body fluid targets also occurred in 
the multiplex.  Because this appeared to occur only within target body fluids, the primers in the 
multiplex were considered to be body fluid specific and were used to amplify all samples prior to 
sequencing.   
 All FAST5 files from the passed and skipped reads folders generated by the MinION 
were basecalled with Albacore, trimmed with Porechop, and loaded into the CLC Genomics 
Workbench software to filter out reads less than 150 bp in length and to map reads to the 
reference genes.  There was a lot a variability in total read counts for each sample in a run.  Due 
to samples not being normalized prior to sequencing preparation, some samples had many more 
reads than others.  Samples with a less than 2,000 total reads were removed prior to analysis.  A 
threshold of 2,000 was chosen based on thresholds set by Hanson et al., in which they count any 
gene marker with at least 500 reads as present. 52  Each sample should contain reads for four 
different genes (two body fluid specific and two housekeeping), so the threshold was set at 2,000 
reads.  Because the number of reads from sample to sample and from run to run is highly 
variable, the relative number of reads of each gene in each body fluid sample was calculated by 
dividing the number of reads of the gene by the total number of reads for the sample.  For each 
body fluid type, the average relative read counts of each gene across all samples was calculated.  
The relative read counts of body fluid specific genes are represented as percentages of total 
reads.  For semen samples, PRM2 appeared to be the most successful marker, contributing to an 
average of 87% of total reads (Figure 3).  PRM2 was the most consistently and highly expressed 
marker in semen samples.  The expression of SEMG1 was less consistent.  SEMG1 was the 
second most highly expressed gene in semen samples, contributing to an average of 11% of the 
total number of reads, but expression was not consistent among all semen samples.  In two 
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semen samples, SEMG1 comprised less than 0.5% of total reads.  Expression of off-target genes 
was minimal.  The number of reads of off-target genes in all eight samples was less than 0.5% of 
the total number of reads.  Like SEMG1, the housekeeping genes, B2M and UBC, were not 
expressed uniformly across all samples.  Only one sample had a significant number of reads of 
B2M (2,381 reads), while all other samples had less than 50.  Two samples had a significant 
number of UBC reads (2,670 and 2,994 reads), but all other samples had less than 10. 
 
 
Figure 3.  Average percentages of relative reads for all targeted genes in semen samples (n=8).  
The yellow bars represent expression of the semen specific genes and the gray bar represent 
housekeeping gene expression.  
	
 
 
 Two saliva samples had less than 2,000 total reads and were eliminated from analysis.  
For the remaining saliva samples, HTN3 appeared to be the most highly and uniformly expressed 
gene in the multiplex, contributing to an average of 62% of all reads (Figure 4).  However, one 
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sample had only 3 reads of HTN3.  STATH, which contributed to 17% of all reads, was not 
expressed as uniformly.  Three samples had 0 reads of STATH.  Of the remaining three samples, 
one had 90,927 reads of STATH, and the other two had 1,526 and 3,514 reads.  Like in the 
semen samples, the housekeeping genes were not expressed uniformly across all saliva samples.  
For three of the samples, the number of reads of B2M was less than 30, and four of the samples 
had less than 10 reads of UBC.  One sample had 24,195 reads of B2M, which contributed to the 
majority of the total reads across all samples.  Only one sample had a significant number of reads 
of UBC (1,728 reads). 
The number of off-target reads was slightly higher than in the semen samples.   There 
were a greater number of PRM1 and SEMG1 reads for several samples.  However, this was not 
seen uniformly across all saliva samples.  Increased number of off-target reads appears to be 
correlated with reuse of the flow cells.  Samples that had a significant number of reads of semen 
genes (greater than 0.5% of total reads) were run on a washed flow cell that had sequenced 
semen samples prior to loading the saliva samples, so the unexpected number of reads is most 
likely due to library carryover from a previous run.  The number of reads of other off-target 
genes (blood, vaginal fluid, and menstrual blood) were less than 0.5% of the total.  
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Figure 4.  Average percentages of relative reads for all targeted genes in saliva samples (n=6). 
The blue bars represent expression saliva specific genes, while the gray bars represent 
housekeeping gene expression.   
 
 
 
 In the blood samples, HBA was the most highly expressed, contributing to 59% of all 
reads (Figure 5).  All samples had at least 1,000X coverage of HBA.  ALAS2 was not expressed 
as highly as HBA, contributing to only 10% of all reads.  In one of the samples, ALAS2 
comprised less than 0.5% of the total number of reads.  The housekeeping genes were more 
uniformly expressed in blood samples than in semen and saliva samples.  B2M comprised more 
than 0.5% of total reads in all samples, with all but one sample having 1,000X coverage.  UBC 
was not expressed very highly in blood samples.  Six of the eight samples had less than 500 
reads of UBC.  There was also unexpectedly high expression of semen and saliva genes in some 
of the samples.  This appears to be due to residual library left after washing the flow cell of a 
previous sequencing run, as the pattern was not seen uniformly across all samples. 
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Figure 5.  Average percentages of relative reads for all targeted genes in blood samples (n=8).  
The red bars represent expression of blood specific genes, while the gray bars represent 
housekeeping gene expression.  
 
 
 
 One of the vaginal fluid samples had less than 2,000 total reads and was removed from 
the analysis.  For the remaining seven samples, CYP2B7P1 appeared to be highly and uniformly 
expressed in all samples, contributing to 34% of all reads (Figure 6).  However, in one sample, 
the number of CYP2B7P1 reads was only 124.  In the other six samples, there was more than 
10,000X coverage of CYP2B7P1.  MYOZ1 was not observed in vaginal fluid samples.  Highest 
number of reads obtained for MYOZ1 was 958.  MYOZ1 comprised less than 0.5% of total reads 
in all other samples.  Both housekeeping genes were heavily expressed in vaginal fluid samples.  
All samples had greater than 5,000X coverage of UBC, contributing to 51% of all reads.  B2M 
was more sporadically expressed than UBC, with three of the samples having less than 500 reads 
of B2M.  There were an unexpected number of reads of SEMG1, HBA, and MMP7 in one 
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vaginal fluid sample.  In all other samples, the number of off-target reads was less than 0.5% of 
the total. 
 
Figure 6.  Average percentages of relative reads for all targeted genes in vaginal fluid samples 
(n=7).  The green bars represent expression of vaginal fluid specific genes, and the gray bars 
represent housekeeping genes expression.  
 
 
 
  In the menstrual blood sample analyzed, the two most highly expressed genes 
were HBA and B2M, which comprised 34.9% and 30.8% of all reads, respectively (Figure 7).  
UBC comprised 17% of all reads and the vaginal fluid gene CYP2B7P1 comprised 8.4% of all 
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reads.  A significant number of reads was obtained for the menstrual blood marker MMP7 (2,925 
reads), but no reads of MMP10 were observed.   
 
 
Figure 7.  Percentages of relative reads for all targeted genes in one menstrual blood sample.  
The brown bars represent expression of menstrual blood genes, green bars represent expression 
of vaginal fluid specific genes, red bars represent expression of blood genes, and gray bars 
represent expression of housekeeping genes. 
 
 
 
 The number of on and off-target reads for all samples, as well as the percentage of off-
target reads were compared (Table 8).  For all body fluid types, the numbers of on-target reads 
(body fluid specific and housekeeping gene reads) comprised the majority of all reads.  Semen 
and menstrual blood samples had the lowest percentage of off-target reads.  There was 
unexpected expression of off-target genes in saliva, blood, and vaginal fluid samples.  However, 
both saliva and blood samples were run on flow cells that had been previously used and washed.  
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There appears to be residual library present after washing of the flow cells, which can account 
for the increased number of off-target reads.  For the vaginal fluid samples, one sample 
comprised the majority of all off-target reads.  An unexpected number of HBA, MMP7, and 
PRM2 gene reads were seen in one sample, but the pattern was not seen uniformly across all 
seven samples.   
 
Table 8.  Total number of reads, as well as the total number of on and off-target reads and the 
percentage of off-target reads, across all body fluid types. 
 
 
 Average relative read counts of body fluid specific genes for each body fluid type are 
represented as percentages (Table 9).  For semen samples, semen specific genes contributed to 
97.7% of reads, with little contribution from any other genes.  For saliva samples, the saliva 
specific genes contributed most of the reads, with more than expected contribution from semen 
genes due to flow cell contamination.  For blood, the largest contribution of reads was from 
blood specific markers, with more than expected contribution from semen genes, which was also 
due to flow cell contamination.  In both vaginal fluid and menstrual blood samples, the largest 
percentage of contribution was from housekeeping genes.  The second largest contribution was 
from vaginal fluid genes in these samples.  In menstrual blood, the contribution from menstrual 
blood genes was low.  However, contribution from blood and housekeeping genes was high. 
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Table 9.  Percent contribution of body fluid specific gene reads based on average relative read 
counts.  Cells highlighted in yellow represent the percent contribution of expected genes 
(biomarkers) for each body fluid type, and cells highlighted in blue represents the percent 
contribution of housekeeping genes. 
 
 
 
 
Sensitivity of long targets 
 The 1:10, 1:100, and 1:1,000 dilutions of semen, blood, and saliva were sequenced in 
triplicate and numbers of reads for each gene were determined (Table 10).  In the semen dilution 
series, PRM2 appeared to be the most successful of the semen markers.  In 1:10 dilutions, PRM2 
was present in all samples and comprised the majority of all reads, while there were less than 50 
reads of SEMG1 across all samples.  Reads of semen genes in the 1:100 dilutions were also 
observed.  More reads of SEMG1 were seen in the 1:100 dilution samples than in the 1:10 
dilutions, with 15,283 reads in one replicate and 4,851 reads in another.  Over 4,000 reads of 
PRM2 were also observed in two of the 1:100 dilution replicates.  The read counts of all other 
genes, including housekeeping genes, were less than 500.  Low read counts were obtained for all 
genes in the 1:1,000 replicates, which had less than 20 reads of semen genes.   
 This assay appears to be sensitive enough to obtain saliva gene reads in 1:10 dilutions of 
saliva.  HTN3 was present in the 1:10 dilutions of saliva.  Two of the samples had more than 
1,000X coverage, with little to no contribution from other genes, including housekeeping genes.  
No reads of STATH were observed in any of the samples.  Very low read counts were obtained 
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for 1:100 and 1:1,000 dilutions of saliva.  One of the 1:100 dilution replicates had higher than 
expected reads of CYP2B7P1 and UBC, which appears to be due to contamination of the flow 
cell with residual library that contained vaginal fluid samples.   
 Reads of blood specific genes (particularly HBA) were able to be obtained down to 
1:1,000 dilutions of blood.  Over 1,000X coverage of HBA was seen in all blood dilution 
samples except for one of the 1:1,000 dilution replicates.  Little to no reads of the other blood 
specific gene, ALAS2, were observed.  There were an unexpectedly high number of reads of 
semen genes in some of these samples, as well as reads of the vaginal fluid gene CYP2B7P1 in 
some samples.  This appears to be correlated with contamination from residual library on the 
flow cell.  In some samples, there were a large number of reads of the housekeeping genes.  
However, samples with more housekeeping gene reads had the same barcodes as vaginal fluid 
samples run previously on the flow cell, and because the high expression of housekeeping genes 
in vaginal fluid samples, it is likely that this is contamination.   
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Table 10. Total number of reads for each sample in the dilution series.  Numbers highlighted in 
green comprise >10% of total reads for the sample, while numbers highlighted in yellow 
represent <5% of total reads and numbers in white comprise <1% of all reads. 
 
 
 Both semen and vaginal fluid genes, as well as housekeeping genes, were observed in the 
vaginal fluid/semen mixtures.  More than 1,000X coverage of SEMG1 was obtained for one of 
the replicates that had 7.5 µl and 15 µl of semen, and for two of the replicates that had 30 µl of 
semen.  Decreasing the volume of semen on swabs appeared to lead to overall decrease in semen 
gene reads, with only one of the samples with 7.5 µl of semen having a significant amount of 
reads.  More than 1,000X coverage of PRM2 was seen in one of the samples with 7.5 µl of 
semen, and in two of the samples with 15 µl and 30 µl of semen.  More than 1,000X coverage of 
the vaginal fluid marker CYP2B7P1 was observed for five of the nine samples.  Little to no reads 
of the other vaginal fluid marker, MYOZ1, were obtained.  Housekeeping genes were heavily 
expressed in nearly all samples.  The total number of reads obtained during this run was lower 
than previous runs.  These samples were run on a flow cell that had previously completed two 
sequencing runs.   
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Figure 8.  Average percentages of relative reads for all targeted genes in vaginal fluid swabs with 
7.5 µl (n=3), 15 µl (n=3), and 30 µl (n=3) of semen. 
 
 
 
MinION performance 
 Despite the 1 µg of recommended DNA input for the 1D Ligation Sequencing Kit, the 
MinION appears to be able to generate high quality data and over 1,000X coverage of target 
genes with little to no off-target reads for most samples.  Contamination of flow cells with 
residual library after washing is apparent, which led to a greater number of off-target reads for 
some samples.  Flow cells were able to be washed and reused 2-4 times, although some flow 
cells had less than the recommended 800 single active pores available after only one use and 
were therefore unusable.  In order to assess the loss of pore function with use of the flow cell, the 
number of reads passing through each pore on one flow cell throughout each consecutive 
sequencing run was obtained with Poretools (Figure 9). 51  There was a clear gradual loss in the 
occupancy of pores with each consecutive run.  The first run on the flow cell (Figure 9 a) had a 
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much higher occupancy than the second (Figure 9 b) and third (Figure 9 c) runs.  Although ONT 
states that flow cells can be washed and reused 3-4 times, the sequencing yield appears to be 
negatively affected by reuse.  The total number of reads obtained in the first run on the flow cell 
was 257,038.  Most of the samples in the first run were vaginal swab samples, which had a high 
number of reads overall.  The total number of reads obtained in the third run on the same flow 
cell was 122,474.  Vaginal swabs samples also comprised a majority of the samples in the third 
run.  Despite having similar sample types, the first run on the flow cell gathered over 2 times as 
many reads as the third run. 
 
 
Figure 9.  Heat map showing the number of reads passed through each nanopore on a flow cell 
during (a) the first run, (b) the second run, and (c) the third run.  Blocks with lighter colors 
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represent nanopores that obtained a greater number of reads, while blocks with darker colors 
represent nanopores that obtained fewer reads.   
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CHAPTER FOUR: DISCUSSION 
 
DNA/RNA co-extraction 
 According to the results of DNA quantification, the DNA/RNA co-extraction method 
using a combination of the RNeasyÒ Kit from QiagenÒ and the PrepFilerÒ Kit from Life 
TechnologiesTM appears to be sufficient to obtain enough DNA to generate full STR profiles.   
Additionally, partial profiles and some complete profiles were obtained for the samples in the 
dilution series.  For the mixture samples, full profiles for both the major and minor contributors 
were able to be obtained.  However, whether or not there is decreased DNA yield with this 
method in comparison to the yield obtained with the PrepfilerÒ Kit alone is unknown.  In order to 
validate this method for use in crime labs, the DNA yield obtained with the adapted PrepfilerÒ 
protocol used in this study should be compared to the yield obtained from extraction with the 
PrepfilerÒ Kit according to the manufacturer’s protocol. Assessment of the performance of some 
commercial DNA/RNA co-extraction methods have shown that there is currently no kit that 
offers optimal extraction of both DNA and RNA. 7, 8  If adding 350 µl RLT Buffer from the 
RNeasy Kit to swabs for the 1 hour incubation at 56°C instead of the PrepfilerÒ Buffer does not 
decrease DNA yield, it could be an efficient co-extraction method for use in crime labs.  The 
RNeasyÒ Kit has the ability to be automated, which would be time-efficient for analysts and 
would decrease the potential for contamination.  With automation, the complete purification of 
DNA and RNA from extract fractions could be done simultaneously.   
 RNA quantification with the Agilent RNA 6000 Pico Kit did not appear to be indicative 
of the true quality of the RNA samples in this study.  All samples were shown to be highly 
degraded, and RIN values were not able to be obtained for many of the samples.  Haas et al. 
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(2009) have suggested that both the Nanodrop and Bioanalyzer RNA kits are unreliable 
measures of quality and quantity of RNA in forensic samples, having achieved positive results 
for mRNA markers despite RIN numbers showing highly or completely degraded RNA. 53  In a 
collaborative EUROFORGEN/EDNAP study, authors suggest using the Quant-iT RiboGreen 
RNA kits with the fluorescence microplate reader (Thermo Fisher Scientific), QuantiFluor RNA 
System (Promega), or the Quant-iT RNA assay with the Qubit (Thermo Fisher Scientific) 
instead, as the Bioanalyzer generally produces low RIN numbers for forensic type samples. 54  
For the purposes of this workflow, RNA quantification may not be necessary, as the main reason 
for quantification of RNA is for the cDNA synthesis reaction.  The RNA input for the 
ProtoscriptÒ First Strand cDNA Synthesis Kit is up to 1 µg of RNA, which would likely never be 
achieved with forensic RNA samples. 37  However, for sequencing kits that require RNA rather 
than cDNA as the input for sequencing, other quantification kits should be explored.   
mRNA analysis 
Marker specificity 
 Bioanalyzer results for singleplex PCR reactions targeting both short and long targets 
show that the primers and gene targets are highly specific.  No amplification of genes was 
observed in any of the off target body fluids, suggesting that both multiplexes are highly specific.  
Although the short amplicons were not used for sequencing, the Bioanalyzer results offer further 
support that the genes targeted in this study are highly specific to their respective body fluid, 
with no observed cross reactivity.  Although no amplification of off-target body fluids was 
observed in the multiplex for long targets, there was some non-specific amplification of 
fragments nearly twice as large as expected fragments within target body fluids.  Sequence data 
suggest that these longer, off target fragments are chimeric reads, as they appear to be a mixture 
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of two target genes within samples.  Artificial chimeras can be generated by PCR due to 
incomplete primer extension, followed by amplification in later cycles. 55  Further optimization 
of the cycling parameters and cDNA input quantity for multiplex PCR may help decrease the 
introduction of chimeras. 
 Sequencing of long amplicons showed that the majority of reads were from the target 
body fluids.  However, most samples had low levels of reads of off-target genes.  It is possible 
that these reads are due to contamination, as all samples were amplified simultaneously.  
However, other studies that analyze mRNA targets through massively parallel sequencing (MPS) 
also had low levels of off-target reads in most samples. Both Hanson et al. and Ingold et al. 
observed read counts for off-target genes in most samples, but the contribution of these reads to 
the total number of reads was minimal. 54, 52  Hanson et al. converted read counts that comprised 
less than 0.5% of total reads to 0 for all analyses. 52  With the large amount of data gathered with 
high throughput sequencing, it appears that the occurrence of off-target gene reads is common in 
body fluid samples, and as long as off-target reads do not comprise a large percentage of the total 
number of reads for the sample, they may be ignored.  However, the thresholds below which 
read counts can be ignored should be clearly defined and validated, particularly with more 
intensive sensitivity and mixture studies than what was explored in this study.   
 An unexpectedly high level of off-target read counts were obtained for some samples.  In 
some saliva samples, there was higher than expected expression levels of semen genes, and 
higher than expected expression levels of semen and saliva genes in some blood samples.  This 
appears to be correlated with reuse of flow cells.  Saliva samples with a greater number of semen 
gene reads had the same barcode as a semen sample analyzed on the same flow cell in a previous 
run.  Likewise, blood samples that had a greater number of semen or saliva gene reads had the 
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same barcode as a semen or saliva sample analyzed on the same flow cell.  Although the 
MinION Wash Kit removes most of the library, there may be some residual library present after 
washing, and therefore ONT recommends barcoding libraries accordingly to eliminate 
contamination during data analysis. 56  The PCR Barcoding Kit I from ONT was used in this 
study, which only contains twelve unique barcodes.  Due to a limited supply of flow cells, 
barcodes were repeated for samples in separate runs on the same flow cell.  This can be avoided 
with the use of the PCR Barcoding Kit 96, which has 96 different barcodes and would therefore 
eliminate the need to repeat barcodes on a single flow cell.   
 There was also an unexpectedly high level of expression of off-target reads in vaginal 
fluid samples that could not be correlated to reuse of the flow cell.  However, one sample 
contributed to 93.4% of the total number off-target reads for all vaginal fluid samples.  The 
majority of the off-target reads were of HBA, followed by PRM2 and MMP7.  It may be that the 
donor who contributed that vaginal fluid sample had just finished menstruating, which would 
account for the high number of blood and menstrual blood gene reads.  The donor may have also 
engaged in vaginal sex within the seven days prior to collection, which would account for the 
high number of semen gene reads.  This high level of expression of off-target reads was not 
observed in the other six vaginal fluid samples.   
 Housekeeping genes were not consistently observed across all sample types.  The 
purpose of the housekeeping genes is to serve as an endogenous positive control and therefore 
should be observed uniformly in all samples that contain RNA.  However, the expression of both 
housekeeping genes was very low in both semen and saliva samples, and only one housekeeping 
gene (B2M) was consistently expressed in blood samples.  Conversely, housekeeping genes were 
highly expressed in vaginal fluid and menstrual blood samples.  The total number of 
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housekeeping gene reads across all vaginal fluid samples was twice that of the total number of 
vaginal fluid gene reads.  This difference in expression may be due to the collection method for 
vaginal fluid and menstrual blood swabs.  Rather than pipetting liquid body fluids onto swabs, 
vaginal fluid samples and the menstrual blood sample were collected with a vaginal swab, which 
will result in collection of both body fluid and epithelial cells.  The high expression level of 
housekeeping genes in these samples may be due to the presence of mRNA from epithelial cells.   
 Another study in which various housekeeping genes were assessed for their ability to 
serve as endogenous positive controls for forensic samples found that, although B2M was the 
most highly expressed gene in their gene panel, it was not expressed uniformly across all 
samples. 57  Authors of a recent study that explored mRNA analysis through MPS suggested that 
housekeeping genes should be left out of analysis, as the total number of reads of housekeeping 
genes far exceeded the total number of body fluid specific reads and therefore led to 
inefficiencies in sequencing of the body fluid specific genes. 52  In this study, the housekeeping 
genes were not informative for semen, saliva, or blood samples.  Additionally, high expression 
levels of these genes in vaginal fluid and menstrual blood samples may have led to a decreased 
read count for the body fluid specific genes.  In the future, it may be beneficial to remove 
housekeeping genes from analysis entirely.  
 In this study, only two genes were targeted for each body fluid.  Addition of gene targets 
to the multiplex should be considered in order to increase the confidence in assignment of body 
fluid source.  For each body fluid type, there was a predominant gene that comprised a majority 
of the reads for each sample.  PRM2 was much more highly expressed than SEMG1, which 
poses an issue, as PRM2 will not be expressed in vasectomized individuals, while SEMG1 
should be present in all seminal fluid.  Other studies have shown that seminogelin genes are 
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highly and consistently expressed and have been able to be successfully targeted for 
identification of semen samples. 12, 53  Likewise, the saliva gene STATH and the blood gene 
ALAS2 have been shown to be highly and consistently expressed in saliva and blood samples, 
but were not expressed consistently in this study. 12, 40  Additionally, the vaginal fluid marker 
MYOZ1 and menstrual blood markers MMP7 and MMP10 did not perform as well in this 
multiplex, although they have been shown to be highly expressed in vaginal fluid and menstrual 
blood samples. 19, 58  This may be due to the length of amplicons targeted in this study.  The 
MinION performs better with longer reads, with recommended target length of at least 300 bp.   
Although some markers (PRM1, HTN3, HBA, and CYP2B7P1) performed well in the 
multiplex, it may be that the other mRNA markers degrade more quickly and therefore were not 
efficiently amplified in the multiplex targeting long fragments.  One study that tested the 
performance of SEMG1 and PRM2 in 33-56 year old semen stains found that, although PRM2 
was detected in up to 56 year old stains, SEMG1 was only detected in fresh semen samples. 59  
This suggests that SEMG1 may degrade much more quickly than PRM2, which could account 
for the decreased number of reads.  A study conducted by Zhao et al. (2016) found that while 
HBA was detected in nearly 90% of 50 year old blood samples, ALAS2 was detected in less than 
3% of 30 year old blood samples and in 0% of 50 year old samples, suggesting that this marker, 
like SEMG1, degrades more quickly. 60  Additionally, both Setzer et al. (2008) and Sirker et al. 
(2016) found that saliva markers (particularly STATH) are more subject to hydrolytic damage 
and are therefore observed less often and more sporadically in older or poorly stored samples. 4, 6  
The occurrence of decreased or sporadically observed reads of body fluid genes in this study 
may be due to degradation of mRNA fragments in the samples.  Although the primers were 
designed to target the innermost portions of mRNA fragments, the efficiency of amplification 
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may be decreased due to shortening of the mRNA fragments.  The read length requirement for 
acquiring high quality data with the MinION would likely not be ideal for highly degraded 
samples, and other markers may be explored that are less subject to degradation for these body 
fluids.  This is supported by the amplicon length data from the samples amplified in the 
multiplex targeting shorter amplicons, as amplification of these genes appeared to be slightly 
more successful with shorter targets. 
Menstrual samples were ordered from Lee Biosolutions and analyzed in the multiplex 
targeting short amplicons.  However, no amplification of blood, vaginal fluid, menstrual blood, 
or housekeeping genes was apparent according to Bioanalyzer results.  Because of this, these 
samples were removed from the analysis.  The storage of these samples prior to receipt is 
unknown, so it may be that the samples were improperly stored and any mRNA was too 
degraded for analysis.  A menstrual blood sample collected by donors via vaginal swab showed 
amplification of vaginal fluid, blood, menstrual blood, and housekeeping genes with both 
multiplexes.  However, no apparent amplification or reads of the menstrual blood gene MMP10 
was observed, which has been shown to be one of the more highly expressed menstrual blood 
biomarkers. 19  Failure of MMP10 amplification could be due to improper primer design or due 
to storage conditions.  More menstrual blood samples should be added for analysis to further 
address this issue, as MMP10 should be present in menstrual blood samples.  However, a 
mixture of blood, vaginal fluid, and menstrual blood genes suggests that the body fluid source 
may be menstrual blood, which should be taken into account during analysis.   
 Although decreased read counts for some genes may be due to degradation of the mRNA, 
it should also be considered that some genes are simply more highly expressed than others.  
Adding genes to the multiplex would allow forensic analysts to see a general pattern of gene 
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expression, which could be a better analysis method than just looking for the presence or absence 
of markers.  Hanson et al. (2018) suggest that observing the general trend of expression of genes 
is informative to the quantity and quality of the mRNA within the sample and therefore this trend 
may be a valuable analysis tool. 52   
Marker sensitivity 
 Semen genes were detected down to 1:100 dilutions of semen, but not in 1:1,000 
dilutions.  The saliva gene HTN3 was only detected in 1:10 dilutions of saliva, but STATH was 
not detected in any of the dilution samples.  The blood gene HBA was detected in down to 
1:1,000 dilutions of blood, but ALAS2 was not detected in most samples.  Another high 
throughput sequencing study showed that saliva and vaginal fluid genes were not detectable 
below 10 ng of RNA for sequencing, while semen and blood genes were detectable down to 5 ng 
of total input. 52  In order to fully assess the sensitivity of this assay, another RNA quantification 
method may need to be implemented to determine the amount of RNA in samples prior to cDNA 
synthesis and amplification, and how varying RNA inputs affect the total read count of body 
fluid specific genes.   
 Semen and vaginal fluid were both detectable in mixture samples, demonstrating the 
ability of multiple body fluids to be detected in two person mixtures with this method.  Other 
mixture combinations should be added in the future, as the ability to detect mixtures of biological 
fluids is important in forensic casework.  The overall sequence yield for the vaginal fluid/semen 
mixture samples appeared to be negatively affected by reuse of the flow cell, as the total 
sequence yield was much less than that of other vaginal swabs analyzed in previous runs.  It is 
likely that a higher number of reads could be achieved by running these samples again on a flow 
cell with a greater number of available pores.   
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MinION performance 
 Despite the 1 µg of DNA input recommended for the Ligation Sequencing Kit 1D, the 
MinION appeared to be able to generate over 1,000X coverage for most body fluid genes.  
Forensic samples, and particularly mRNA samples, are generally of lower quantity and quality 
than what is recommended for the MinION.  Additionally, the MinION has largely been adapted 
for sequencing of very large fragments, which is something that is not compatible with mRNA 
analysis in forensic samples.  Despite this, the MinION was able to successfully sequence 
amplicons 344-440 bp in length generated from low-level samples.  Additionally, the accuracy of 
long read sequencing platforms like the MinION have been known to be lower than that of 
sequencing platforms geared towards sequencing shorter fragments, like the Illumina® MiSeq™.  
However, updates to flow cell chemistry and analysis software have increased the overall 
accuracy of basecalling for the MinION platform. 61  In September of 2017, the Albacore v2.0.1 
software was released, which uses the raw data generated by the MinION for basecalling.  This 
was shown to increase the overall accuracy of reads. 61  Improvements to sequencing kit and flow 
cell chemistry and the analysis software algorithms have expanded the reach of this platform.  
This proof of concept study demonstrates that the MinION sequencer is capable of successfully 
sequencing and identifying mRNA amplicons for body fluid identification in forensic type 
samples. 
 Although the MinION was able to generate high quality sequence data from these 
samples, optimization and further validation of this sequencing method are necessary.  One issue 
that should be addressed in the future is the normalization of barcoded amplicons prior to 
sequencing preparation.  In the end-prepping portion of MinION sequencing workflow with the 
Ligation Sequencing Kit 1D, all barcoded amplicons are pooled to achieve a 45 µl total input 
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volume.  As twelve samples were sequenced at a time, 3.75 µl of each sample were combined to 
achieve the 45 µl input volume.  However, after barcoding, amplicon concentration varied from 
sample to sample.  Normalizing samples according to amplicon concentration may allow for 
more consistent total read counts for each sample on the flow cell, as the total number of read 
counts in this study was highly variable from sample to sample within a sequencing run.  
Additionally, the MinION protocol recommends using 0.2 pmoles of end-prepped DNA for 
adapter ligation.  However, when 0.2 pmoles were added for adapter ligation, the read counts for 
all samples were very low, with a total read count of 10,103 for eleven samples.  Adding the full 
volume of end-prepped DNA (30 µl) without normalization led to acquisition of 10-60 times 
more reads of body fluid genes.   
 Although ONT has developed some low input sequencing kits and protocols during the 
course of this study, they are only suitable for gDNA as input.  A few kits have been developed 
that require RNA or cDNA as input for the sequencing workflow.  One that would be applicable 
to the pre-sequencing workflow designed in this study is the Sequence-specific cDNA-PCR 
sequencing using the cDNA-PCR Sequencing Kits (SQK-PCS108).  This protocol uses the 
strand-switching method of cDNA synthesis with user designed primers to allow for targeted 
cDNA synthesis, followed by PCR of full length transcripts and rapid adapter ligation. 62  This 
method could potentially decrease the total workflow time.  Additionally, the workflow is 
recommended for low RNA input.  However, it appears to select full length cDNA transcripts, 
which may not be achievable with forensic samples.  Additionally, the kit is not compatible with 
any barcoding kits at the moment, although it is likely that barcoding will be added in the future.   
Use of the strand-switching method of cDNA synthesis may increase sequencing yield.  
Strand-switching cDNA synthesis uses the Moloney murine leukemia virus (MMLV) reverse 
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transcriptase to add additional nucleotides as it reaches the 5’ end of mRNA to act as a binding 
site for the template switching (TS) oligo. 63  Binding of the TS oligo allows MMLV to switch 
strands and continue cDNA synthesis to complete the 5’ end of the transcript, which has been 
shown to increase overall cDNA production. 63  Additionally, optimization of the 1D PCR 
barcoding protocol should be explored in order to increase sequencing yield.  Wei et al. 
demonstrated that, with the Genomic Sequencing Kit protocol, decreasing the volume of the 
adapter ligation reaction increased production of adapter ligated sequences by 48%, and adding a 
1-2 hour incubation at 4°C after adapter ligation increased products by 61-63%. 64  Decreasing 
the adapter ligation reaction volume would extend the use of the sequencing kit and therefore 
decrease the cost per sample, as the adapter ligation mix is often the first reagent in the kit to be 
used up. 
Flow cells appear to experience a decrease in yield after reuse.  The occupancy of a flow 
cell examined in this study decreased drastically after three consecutive runs, which led to 
decreased overall sequence yield.  Because the flow cells are currently quite expensive, this 
poses a problem.  ONT has two options for washing flow cells.  Both methods begin with 
addition of Solution A in the Wash Kit, which releases DNA strands from the nanopores in the 
membrane. 65  After loading Solution A, Solution B can be added to remove the library and prime 
the flow cell for loading of the next library immediately, or Storage Buffer can be added if the 
flow cell will be stored. 65  If Solution B is added, a platform QC cannot be completed to assess 
the number of single active pores available for sequencing.  Platform QC of flow cells with 
Storage Buffer must be completed prior to adding the next library.  With the three consecutive 
runs on the single flow cell analyzed in this study, Solution B was added for washing and the 
next library was added immediately without doing a platform QC on the flow cell.  In the future, 
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it may be wise to alternate flow cells and add Storage Buffer for flow cell washing, rather than 
Solution B.  This would allow for a platform QC to be completed on a flow cell prior to every 
run in order to ensure enough pores are available for efficient sequencing of libraries.   
The cost per sample in this study, with reuse of flow cells 2-4 times, was $60.21-$78.96.  
The cost per sample could be brought down with further optimization of the sequencing 
workflow.  In this study, 12 barcoded samples were combined into each sequencing reaction.  
However, with the 96 barcode kit, more samples could be pooled into one sequencing reaction.  
Additionally, if flow cells are ordered in bulk, the price of individual flow cells decreases from 
$900 to $475.  Flow cells are recommended to be used within 8 weeks of receipt, so ordering of 
flow cells in bulk would be dependent on the throughput of individual crime labs.  Reuse of flow 
cells decreases the number of active pores, which would decrease sequence yield for subsequent 
runs.  Oxford Nanopore Technologies recommends only using flow cells with at least 800 single 
active pores, which is determined by completing a platform QC with MinKNOW prior to loading 
the library.  Some flow cells maintained 800 active pores after 2 to 3 uses, while the pore count 
for other flow cells fell below 800 pores after only one use.  Flow cells also appear to lose more 
single active pores after longer sequencing runs.  Because of this, sequencing runs were stopped 
after 4-5 hours in this study.  Allowing sequencing runs to continue for longer may increase the 
amount of sequence data generated, so the optimal run time for these types of samples should be 
determined in order to maximize data acquisition while also minimizing the cost per sample.   
 The MinION platform should also be compared to other sequencing platforms, like the 
Illumina® platform.  The MinION method is appealing due to its small size, simple setup, simple 
library preparation, and real-time data analysis.  The library preparation for the MinION is quick 
and simple, so it would be easy to train analysts to use this method.  The cloud-based EPI2ME 
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software allows the user to monitor the number, size, and quality of reads generated during a 
sequencing run from anywhere, allowing the user to stop the sequencing run once a sufficient 
amount of data is obtained and load the next library.  Additionally, the price of the sequencer is 
only $1,000, although the reagents and flow cells are still expensive.  However, there are some 
drawbacks to using the MinION.  The longevity of the flow cells appears to be unpredictable, 
which could cost crime labs more money than anticipated.  The MinION also requires longer 
fragments of DNA/RNA in order to be able to obtain high quality sequences, which is not ideal 
for degraded forensic samples.  Conversely, the Illumina® platform offers the potential to target 
much smaller fragments and more options for low quantity and quality samples.  Other 
sequencing platforms should be explored with this body fluid identification method in order to 
compare the overall quantity and quality of data generated to that obtained with the MinION.  
The capability of other platforms to be integrated into the workflow of crime labs should also be 
assessed in comparison to that of the MinION.   
Conclusions 
 This proof of concept study explored the ability of the MinION sequencer to generate 
high quality sequences from forensic mRNA samples for body fluid identification purposes.  A 
DNA/RNA co-extraction method allowed for the generation of DNA and RNA profiles from 
single half swabs with semen, saliva, blood, vaginal fluid, and menstrual blood.  A multiplex 
PCR designed to target two body fluid specific genes per body fluid type and two housekeeping 
genes successfully amplified cDNA in body fluid samples with little to no cross reactivity.  By 
targeting longer mRNA fragments (>300 bp) through PCR, and with preparation with the 1D 
Ligation Sequencing Kit by ONT, high quality sequences were mapped to reference genes with 
>1,000X coverage of expected gene in most samples and even in diluted samples and mixtures.  
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Although the method in this study was successfully used to identify body fluid specific mRNAs, 
further optimization is needed to increase sequence yield.  Additionally, the ability of this 
sequencer to generate high quality data from more degraded samples should be assessed, since 
the length of the fragments targeted in this study may not be ideal in more degraded, older 
samples.  Comparison of this platform to other high throughput sequencing platforms in the 
future would give the forensic community better insight into the benefits and drawbacks of 
introducing these different body fluid identification methods into crime labs.  Overall, the 
MinION appears to be capable of generating sequences with much smaller input quantities than 
recommended when PCR is integrated into the workflow, allowing it to be adapted for use with 
forensic type samples.    
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APPENDIX 
 
 
Table A1.  DNA quantity and the completeness of profile based on autosomal STR loci for all 
body fluid samples.   
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Table A2.  DNA quantity and the completeness of profile based on autosomal STR loci for 3 
replicates of 1:10, 1:100, and 1:1,000 dilutions of semen, saliva, and blood. 
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Table A3. DNA quantity and the completeness of profile based on autosomal STR loci for 
vaginal swabs with 7.5 µl, 15 µl, and 30 µl of semen for 3 sets of donors.   
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Table A4.  Total number of reads for each body fluid sample analyzed in this study.  Numbers 
highlighted in green comprise >10% of total reads for the sample, while numbers highlighted in 
yellow represent <5% of total reads and numbers in while comprise <1% of all reads. 
 
 
Table A5.  Total number of reads for each sample in the vaginal fluid/semen mixture samples.  
Numbers highlighted in green comprise >10% of total reads for the sample, while numbers 
highlighted in yellow represent <5% of total reads and numbers in while comprise <1% of all 
reads. 
 
